What can we learn from molecular dynamics simulations for GPCR drug design?

Computational and Structural Biotechnology Journal

Volumn 13, Issue , 2015, Pages 111-121

  Tautermann, Christofer S ^a   Seeliger, Daniel ^a   Kriegl, Jan M ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

CC chemokine receptor 3; GPCR; Homology modeling; Molecular dynamics simulations; Muscarinic acetylcholine receptor 3; Water network

Indexed keywords

CC CHEMOKINE RECEPTOR 3; CHEMOKINE RECEPTOR; G PROTEIN COUPLED RECEPTOR; MUSCARINIC M3 RECEPTOR; TYROSINE; UNCLASSIFIED DRUG; WATER;

ARTICLE; DRUG DESIGN; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL;

EID: 84937731056     PISSN: None     EISSN: 20010370     Source Type: Journal    
DOI: 10.1016/j.csbj.2014.12.002     Document Type: Article

References (83)

1. K. Lundstrom Latest development in drug discovery on G protein-coupled receptors Curr Protein Pept Sci 7 2006 465 470
2. P.M. Giguere, W.K. Kroeze, and B.L. Roth Tuning up the right signal: chemical and genetic approaches to study GPCR functions Curr Opin Cell Biol 27 2014 51 55
3. J.P. Overington, B. Al-Lazikani, and A.L. Hopkins How many drug targets are there? Nat Rev Drug Discov 5 2006 993 996
4. A. Wise, K. Gearing, and S. Rees Target validation of G-protein coupled receptors Drug Discov Today 7 2002 235 246
5. S.L. Garland Are GPCRs still a source of new targets? J Biomol Screen 18 2013 947 966
6. R. Fredriksson, M.C. Lagerstrom, L.G. Lundin, and H.B. Schioth The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints Mol Pharmacol 63 2003 1256 1272
7. S.H.S. Lin, and O. Civelli Orphan G protein-coupled receptors: targets for new therapeutic interventions Ann Med 36 2004 204 214
8. E. Alvarez-Curto, R.J. Ward, and G. Milligan Novel assay technologies for the discovery of G protein-coupled receptor drugs Neuromethods 60 2011 231 253
9. I. Beets, M. Lindemans, T. Janssen, and P. Verleyen Deorphanizing G protein-coupled receptors by a calcium mobilization assay Methods Mol Biol 789 2011 377 391
10. M. Boehm, D. Hepworth, P.M. Loria, L.D. Norquay, K.J. Filipski, J.E. Chin, and et al. Chemical probe identification platform for orphan GPCRs using focused compound screening: GPR39 as a case example ACS Med Chem Lett 4 2013 1079 1084
11. K. Lundstrom An overview on GPCRs and drug discovery: structure-based drug design and structural biology on GPCRs Methods Mol Biol 552 2009 51 66
12. R.C. Stevens, V. Cherezov, V. Katritch, R. Abagyan, P. Kuhn, H. Rosen, and et al. The GPCR Network: a large-scale collaboration to determine human GPCR structure and function Nat Rev Drug Discov 12 2013 25 34
13. C.S. Tautermann GPCR structures in drug design, emerging opportunities with new structures Bioorg Med Chem Lett 24 2014 4073 4079
14. M. Congreve, C. Langmead, and F.H. Marshall The use of GPCR structures in drug design Adv Pharmacol 62 2011 1 36
15. C.S. Tautermann The use of G-protein coupled receptor models in lead optimization Futur Med Chem 3 2011 709 721
16. S. Topiol X-ray structural information of GPCRs in drug design: what are the limitations and where do we go? Expert Opin Drug Discov 8 2013 607 620
17. S. Weyand, and C.G. Tate Structure-based drug design applied to GPCRs: the holy grail realized Biochemist 36 2014 23 27
18. M. Congreve, G. Chessari, D. Tisi, and A.J. Woodhead Recent developments in fragment-based drug discovery J Med Chem 51 2008 3661 3680
19. D. Joseph-McCarthy, A.J. Campbell, G. Kern, and D. Moustakas Fragment-based lead discovery and design J Chem Inf Model 54 2014 693 704
20. C.W. Murray, M.L. Verdonk, and D.C. Rees Experiences in fragment-based drug discovery Trends Pharmacol Sci 33 2012 224 232
21. S.P. Andrews, G.A. Brown, and J.A. Christopher Structure-based and fragment-based GPCR drug discovery ChemMedChem 9 2014 256 275
22. A. Visegrády, and G.M. Keser Fragment-based lead discovery on G-protein-coupled receptors Expert Opin Drug Discov 8 2013 811 820
23. J.A. Christopher, J. Brown, A.S. Doré, J.C. Errey, M. Koglin, F.H. Marshall, and et al. Biophysical fragment screening of the beta1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design J Med Chem 56 2013 3446 3455
24. M. Congreve, R.L. Rich, D.G. Myszka, F. Figaroa, G. Siegal, and F.H. Marshall Fragment screening of stabilized G-protein-coupled receptors using biophysical methods Methods Enzymol 493 2011 115 136
25. D. Chen, J.C. Errey, L.H. Heitman, F.H. Marshall, A.P. Ijzerman, and G. Siegal Fragment screening of GPCRs using biophysical methods: identification of ligands of the adenosine A(2A) receptor with novel biological activity ACS Chem Biol 7 2012 2064 2073
26. M. Congreve, S.P. Andrews, A.S. Doré, K. Hollenstein, E. Hurrell, C.J. Langmead, and et al. Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design J Med Chem 55 2012 1898 1903
27. S. Schlyer, and R. Horuk I want a new drug: G-protein-coupled receptors in drug development Drug Discov Today 11 2006 481 493
28. N. Bertheleme, P.S. Chae, S. Singh, D. Mossakowska, M.M. Hann, K.J. Smith, and et al. Unlocking the secrets of the gatekeeper: methods for stabilizing and crystallizing GPCRs Biochim Biophys Acta 1828 2013 2583 2591
29. S. Costanzi Modeling G protein-coupled receptors and their interactions with ligands Curr Opin Struct Biol 23 2013 185 190
30. A. Heifetz, O. Barker, G.B. Morris, R.J. Law, M. Slack, and P.C. Biggin Toward an understanding of agonist binding to human Orexin-1 and Orexin-2 receptors with G-protein-coupled receptor modeling and site-directed mutagenesis Biochemistry 52 2013 8246 8260
31. D. Latek, P. Pasznik, T. Carlomagno, and S. Filipek Towards improved quality of GPCR models by usage of multiple templates and profile-profile comparison PLoS One 8 2013 e56742
32. A.M. Preininger, J. Meiler, and H.E. Hamm Conformational flexibility and structural dynamics in GPCR-mediated G protein activation: a perspective J Mol Biol 425 2013 2288 2298
33. S.G. Rasmussen, B.T. DeVree, Y. Zou, A.C. Kruse, K.Y. Chung, T.S. Kobilka, and et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex Nature 477 2011 549 555
34. S.G. Rasmussen, H.J. Choi, J.J. Fung, E. Pardon, P. Casarosa, P.S. Chae, and et al. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor Nature 469 2011 175 180
35. V. Cherezov, D.M. Rosenbaum, M.A. Hanson, S.G. Rasmussen, F.S. Thian, T.S. Kobilka, and et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor Science 318 2007 1258 1265
36. K.J. Kohlhoff, D. Shukla, M. Lawrenz, G.R. Bowman, D.E. Konerding, D. Belov, and et al. Cloud-based simulations on Google Exacycle reveal ligand modulation of GPCR activation pathways Nat Chem 6 2014 15 21
37. R.O. Dror, D.H. Arlow, P. Maragakis, T.J. Mildorf, A.C. Pan, H. Xu, and et al. Activation mechanism of the beta2-adrenergic receptor Proc Natl Acad Sci 108 2011 18684 18689
38. A. Bruno, and G. Costantino Molecular dynamics simulations of G protein-coupled receptors Mol Inform 31 2012 222 230
39. R.O. Dror, R.M. Dirks, J.P. Grossman, H. Xu, and D.E. Shaw Biomolecular simulation: a computational microscope for molecular biology Annu Rev Biophys 41 2012 429 452
40. H. Zhao, and A. Caflisch Molecular dynamics in drug design Eur J Med Chem 2014 10.1016/j.ejmech.2014.08.004
41. J.D. Durrant, and J.A. McCammon Molecular dynamics simulations and drug discovery BMC Biol 9 2011 71
42. M.J. Harvey, and G. De Fabritiis High-throughput molecular dynamics: the powerful new tool for drug discovery Drug Discov Today 17 2012 1059 1062
43. P. Cozzini, G.E. Kellogg, F. Spyrakis, D.J. Abraham, G. Costantino, A. Emerson, and et al. Target flexibility: an emerging consideration in drug discovery and design J Med Chem 51 2008 6237 6255
44. F. Feixas, S. Lindert, W. Sinko, and J.A. McCammon Exploring the role of receptor flexibility in structure-based drug discovery Biophys Chem 186 2014 31 45
45. O. Guvench, and A.D. Mackerell Jr. Computational fragment-based binding site identification by ligand competitive saturation PLoS Comput Biol 5 2009 e1000435
46. C.D. Christ, and T. Fox Accuracy assessment and automation of free energy calculations for drug design J Chem Inf Model 54 2014 108 120
47. N. Hansen, and W.F. Van Gunsteren Practical aspects of free-energy calculations: a review J Chem Theory Comput 10 2014 2632 2647
48. Q. Tan, Y. Zhu, J. Li, Z. Chen, G.W. Han, I. Kufareva, and et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex Science 341 2013 1387 1390
49. Chemical Computing Group MOE - Molecular operating environment 2010 Chemical Computing Group Montreal
50. M.A. Marti-Renom, A.C. Stuart, A. Fiser, R. Sanchez, F. Melo, and A. Sali Comparative protein structure modeling of genes and genomes Annu Rev Biophys Biomol Struct 29 2000 291 325
51. A. Sali, and T.L. Blundell Comparative protein modelling by satisfaction of spatial restraints J Mol Biol 234 1993 779 815
52. J.M. Kriegl, D. Martyres, M.A. Grundl, R. Anderskewitz, H. Dollinger, G. Rast, and et al. Rodent selectivity of piperidine-4-yl-1H-indoles, a series of CC chemokine receptor-3 (CCR3) antagonists: insights from a receptor model Bioorg Med Chem Lett 2014 http://dx.doi.org/10.1016/j.bmcl.2014.11.063
53. B. Hess, C. Kutzner, D. van der Spoel, and E. Lindahl GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation J Chem Theory Comput 4 2008 435 447
54. C.S. Tautermann, T. Kiechle, D. Seeliger, S. Diehl, E. Wex, R. Banholzer, and et al. Molecular basis for the long duration of action and kinetic selectivity of tiotropium for the muscarinic M3 receptor J Med Chem 56 2013 8746 8756
55. O. Berger, O. Edholm, and F. Jahnig Molecular dynamics simulations of a fluid bilayer of dipalmitoylphosphatidylcholine at full hydration, constant pressure, and constant temperature Biophys J 72 1997 2002 2013
56. R.B. Best, and G. Hummer Optimized molecular dynamics force fields applied to the helix-coil transition of polypeptides J Phys Chem B 113 2009 9004 9015
57. K. Lindorff-Larsen, S. Piana, K. Palmo, P. Maragakis, J.L. Klepeis, R.O. Dror, and et al. Improved side-chain torsion potentials for the Amber ff99SB protein force field Proteins 78 2010 1950 1958
58. H.J.C. Berendsen, J.R. Grigera, and T.P. Straatsma The missing term in effective pair potentials J Phys Chem 91 1987 6269 6271
59. I.S. Joung, and T.E. Cheatham III Determination of alkali and halide monovalent ion parameters for use in explicitly solvated biomolecular simulations J Phys Chem B 112 2008 9020 9041
60. J. Wang, R.M. Wolf, J.W. Caldwell, P.A. Kollman, and D.A. Case Development and testing of a general amber force field J Comput Chem 25 2004 1157 1174
61. M.J. Frisch, G.W. Trucks, H.B. Schlegel, G.E. Scuseria, M.A. Robb, J.R. Cheeseman, and et al. Gaussian 09, Revision B.01. Gaussian 09, Revision B.01 2009 Gaussian, Inc. Wallingford CT
62. A. Sousa da Silva, and W. Vranken ACPYPE - AnteChamber PYthon Parser interfacE BMC Res Notes 5 2012 367
63. M.G. Wolf, M. Hoefling, C. Aponte-Santamaría, H. Grubmüller, and G. Groenhof g-membed: efficient insertion of a membrane protein into an equilibrated lipid bilayer with minimal perturbation J Comput Chem 31 2010 2169 2174
64. H.J.C. Berendsen, J.P.M. Postma, W.F. van Gunsteren, A. DiNola, and J.R. Haak Molecular dynamics with coupling to an external bath J Chem Phys 81 1984 3684 3690
65. G. Bussi, D. Donadio, and M. Parrinello Canonical sampling through velocity rescaling J Chem Phys 126 2007 014101 014107
66. M. Parrinello, and A. Rahman Polymorphic transitions in single crystals: a new molecular dynamics method J Appl Phys 52 1981 7182 7190
67. U. Essmann, L. Perera, M.L. Berkowitz, T. Darden, H. Lee, and L.G. Pedersen A smooth particle mesh Ewald method J Chem Phys 103 1995 8577 8593
68. S. Miyamoto, and P.A. Kollman Settle: an analytical version of the SHAKE and RATTLE algorithm for rigid water models J Comput Chem 13 1992 952 962
69. B. Hess, H. Bekker, H.J.C. Berendsen, and J.G.E.M. Fraaije LINCS: a linear constraint solver for molecular simulations J Comput Chem 18 1997 1463 1472
70. K.A. Feenstra, B. Hess, and H.J.C. Berendsen Improving efficiency of large time-scale molecular dynamics simulations of hydrogen-rich systems J Comput Chem 20 1999 786 798
71. A. Viola, and A.D. Luster Chemokines and their receptors: drug targets in immunity and inflammation Annu Rev Pharmacol Toxicol 48 2008 171 197
72. A. Bahl, B. Springthorpe, and R. Riley Chemokine CCR3 antagonists T.T. Hansel, P.J. Barnes, New drugs and targets for asthma and COPD 39th ed. 2010 Karger AG Basel 153 159
73. R.J. Trabanino, S.E. Hall, N. Vaidehi, W.B. Floriano, V.W. Kam, and W.A. Goddard 3rd First principles predictions of the structure and function of g-protein-coupled receptors: validation for bovine rhodopsin Biophys J 86 2004 1904 1921
74. E.L. Wise, C. Duchesnes, P.C. da Fonseca, R.A. Allen, T.J. Williams, and J.E. Pease Small molecule receptor agonists and antagonists of CCR3 provide insight into mechanisms of chemokine receptor activation J Biol Chem 282 2007 27935 27943
75. J.S. Surgand, J. Rodrigo, E. Kellenberger, and D. Rognan A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors Proteins 62 2006 509 538
76. D. Martyres, M. Hoffmann, P. Seither, and T. Bouyssou Novel substituted piperidyl-propane-thiols WO2008/049875 A1[WO2008/049875] 2008
77. Global Strategy for the Diagnosis, Management and Prevention of COPD Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014 Available from: http://www.goldcopd.org/
78. M. Cazzola, C.P. Page, L. Calzetta, and M.G. Matera Pharmacology and therapeutics of bronchodilators Pharmacol Rev 64 2012 450 504
79. A.C. Kruse, J. Hu, A.C. Pan, D.H. Arlow, D.M. Rosenbaum, E. Rosemond, and et al. Structure and dynamics of the M3 muscarinic acetylcholine receptor Nature 482 2012 552 556
80. P. Schmidtke, F.J. Luque, J.B. Murray, and X. Barril Shielded hydrogen bonds as structural determinants of binding kinetics: application in drug design J Am Chem Soc 133 2011 18903 18910
81. V. Katritch, G. Fenalti, E.E. Abola, B.L. Roth, V. Cherezov, and R.C. Stevens Allosteric sodium in class A GPCR signaling Trends Biochem Sci 39 2014 233 244
82. V.S. Pande, K. Beauchamp, and G.R. Bowman Everything you wanted to know about Markov State Models but were afraid to ask Methods 52 2010 99 105
83. J.H. Prinz, H. Wu, M. Sarich, B. Keller, M. Senne, M. Held, and et al. Markov models of molecular kinetics: generation and validation J Chem Phys 134 2011 174105